These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 37240080)

  • 1. SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases.
    Di Costanzo A; Esposito G; Indolfi C; Spaccarotella CAM
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
    Kale A; Sharma A; Anders HJ; Gaikwad AB
    Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
    Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
    Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
    PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.
    Säemann M; Cejka D; Schmaldienst S; Rosenkranz AR; Mayer G
    Wien Klin Wochenschr; 2023 Feb; 135(3-4):97-109. PubMed ID: 36251099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review.
    Maxson R; Starr J; Sewell J; Lyas C
    Clin Ther; 2024 Jan; 46(1):e23-e28. PubMed ID: 37951783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EMPA-KIDNEY: empagliflozin in chronic kidney disease].
    Delanaye P; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):24-28. PubMed ID: 36634063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review.
    Scheen AJ
    Expert Rev Endocrinol Metab; 2023; 18(4):271-282. PubMed ID: 37154218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.
    Mark PB; Sarafidis P; Ekart R; Ferro CJ; Balafa O; Fernandez-Fernandez B; Herrington WG; Rossignol P; Del Vecchio L; Valdivielso JM; Mallamaci F; Ortiz A; Nistor I; Cozzolino M
    Nephrol Dial Transplant; 2023 Oct; 38(11):2444-2455. PubMed ID: 37230946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
    Verma S; Mudaliar S; Greasley PJ
    Adv Ther; 2024 Jan; 41(1):92-112. PubMed ID: 37943443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.